Moderna's stock surged 14% to a 52-week high following an FDA advisory panel's unanimous endorsement of its flu vaccine for adults 50 and older, a key step before the August 2026 approval date. The rally also reflects optimism from Moderna's recent Science Day highlighting its expansion into oncology and autoimmune diseases, alongside strong Q1 revenue growth of 264% year-over-year. Despite the surge, analysts remain cautious with a consensus price target below current levels and insider selling noted. Investors will watch the upcoming FDA decision and Phase 3 trial results for further direction.

More News (MRNA)

Moderna gains analyst confidence with FDA backing for flu vaccine and pipeline expansion.

Moderna received a unanimous 9-0 endorsement from an FDA advisory panel for its seasonal flu vaccine, mFlusiva, boosting its approval chances. Piper Sandler reiterated an Overweight rating and raised Moderna's price target to $77, reflecting strong a...

Analyst Insights

Bullish

2 days ago